Recombinant elastin, preparation method and use thereof

By designing and expressing recombinant elastin with high homology amino acid sequences, the problems of poor biocompatibility and low biological activity of existing elastin products are solved, and good skin repair effects and industrial production possibilities are achieved.

CN117551184BActive Publication Date: 2024-11-22SHAANXI GUANTU BIOTECHNOLOGY CO LTD
View PDF 0 Cites 6 Cited by

Patent Information

Application Number
CN202311478134.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-07
Publication Date
2024-11-22
Estimated Expiration
2043-11-07

AI Technical Summary

Technical Problem

Existing elastin products have poor biocompatibility and low bioactivity in the field of skin repair, making it difficult to satisfy the application effect.

Method used

By designing the amino acid sequence of recombinant elastin, it contains at least one sequence that is highly homologous to the amino acid sequence of elastin in nature, and is expressed in the host cell through genetic engineering methods, improving its water solubility and low immunogenicity, forming a good Biocompatibility and bioactivity.

Benefits of technology

Recombinant elastin significantly promotes the proliferation, adhesion and migration of keratinocytes and fibroblasts in human skin, has significant skin repair functions, is suitable for a variety of medical and cosmetic fields, has low expression difficulty, simple and easy to produce in industrialized production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117551184B_ABST
    Figure CN117551184B_ABST
Patent Text Reader

Abstract

The present invention provides a recombinant elastin, wherein the amino acid sequence of the recombinant elastin comprises at least one of the following: (1) an amino acid sequence as shown in SEQ ID NO.1 comprising N tandemly connected amino acids, wherein N represents an integer ≥1; and (2) an amino acid sequence having ≥45% homology with the amino acid sequence as shown in SEQ ID NO.1. Compared with elastin from animal sources, the recombinant elastin of the present invention has the characteristics of better water solubility and lower immunogenicity, exhibits good biocompatibility and biological activity, can significantly promote the proliferation, adhesion and migration of human skin keratinocytes and fibroblasts, has a repairing function for scalded skin, and can thus be widely used in skin repair dressings, fillers, implants, artificial blood vessels, artificial skin, drug delivery carriers, artificial bones, artificial cartilages, artificial corneas, biomaterials, medical devices, cosmetics and other fields.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of gene engineering, and in particular to a recombinant elastin protein, a preparation method and an application thereof. Background Art

[0002] Elastin is a protein that exists in organs and tissues and gives them elasticity. It is a highly elastic protein found in connective tissue and other types of tissues. It is mainly found in the human heart, skin, lungs, blood vessels and ligaments, etc., and maintains the normal physiological functions of the body. Elastin in nature is a low-water-soluble, amorphous, highly hydrophobic and extensively cross-linked extracellular matrix protein. About 90% of elastic fibers are composed of elastin, and the remaining 10% are composed of glycoproteins.

[0003] Currently, naturally occurring elastin or non-naturally occurring elastin has been used in many fields such as the food field. However, most current elastin products have the defects of poor biocompatibility and low biological activity, and the effect of using them in skin repair is not satisfactory. Summary of the invention

[0004] Therefore, the technical problem to be solved by the present invention is to provide a recombinant elastin, a preparation method and a use thereof, wherein the recombinant elastin has good biocompatibility and bioactivity and has a strong skin modification function.

[0005] To this end, the present invention provides the following technical solutions:

[0006] A recombinant elastin protein, wherein the amino acid sequence of the recombinant elastin protein comprises at least one of the following:

[0007] (1) comprising N tandem amino acid sequences as shown in SEQ ID NO. 1; N represents an integer ≥ 1;

[0008] (2) An amino acid sequence having ≥45% homology with the amino acid sequence shown in SEQ ID NO.1.

[0009] Optionally, N is expressed as ≥1 and ≤10.

[0010] Optionally, N=2.

[0011] A biological material comprising any of the following:

[0012] (1) a nucleic acid molecule encoding the recombinant elastin;

[0013] (2) A recombinant vector containing the nucleic acid molecule described in (1);

[0014] (3) A host cell containing the nucleic acid molecule described in (1) or the recombinant vector described in (2).

[0015] Optionally, the nucleic acid molecule is codon optimized;

[0016] Optionally, the nucleic acid molecule includes a nucleotide sequence of an NcoⅠ restriction site, a HindⅢ restriction site, a stop codon and / or a 6×His tag;

[0017] Optionally, the nucleotide sequence of the NcoⅠ restriction site is 5'-CCATGG-3';

[0018] Optionally, the nucleotide sequence of the HindⅢ restriction site is 5'-AAGCTT-3';

[0019] Optionally, the nucleotide sequence of the stop codon is 5'-TAA-3';

[0020] Optionally, the nucleotide sequence of the 6×His tag is 5′-CATCACCACCATCATCAC-3′.

[0021] Optionally, the starting vector of the recombinant vector includes pCold, pET or pPIC9K.

[0022] Optionally, the host cell includes Escherichia coli, Pichia pastoris or Saccharomyces cerevisiae.

[0023] A method for preparing the recombinant elastin comprises connecting the nucleic acid molecule in the biological material with the vector to obtain the recombinant vector, then transforming the host cell, fermenting, collecting the bacterial precipitate, crushing to obtain the supernatant, and purifying.

[0024] A use of the recombinant elastin in preparing products in the fields of cosmetics, medical beauty or medicine.

[0025] Optionally, the method includes use in preparing skin repair dressings, fillers, implants, artificial blood vessels, artificial skin, drug delivery carriers, artificial bones, artificial cartilages, artificial corneas, medical devices or cosmetics;

[0026] Optionally, use in preparing a product for promoting epidermal keratinization in the skin;

[0027] Optionally, use in preparing a product for repairing the epidermis of the skin;

[0028] Optionally, use in the preparation of a product for repairing the dermis in the skin;

[0029] Optionally, use in the preparation of an injectable product;

[0030] Optionally, use in the preparation of medical device products;

[0031] Optionally, use in the preparation of products for repairing and healing wounds;

[0032] Optionally, the invention can be used for preparing products for repairing and healing skin burns.

[0033] A skin repair product comprises the recombinant elastin as an active ingredient and also comprises an acceptable carrier or excipient.

[0034] The technical solution of the present invention has the following advantages:

[0035] 1. A recombinant elastin provided by the present invention, wherein the amino acid sequence of the recombinant elastin comprises at least one of the following: (1) an amino acid sequence as shown in SEQ ID NO.1 comprising N tandemly connected amino acids; N represents an integer ≥1; (2) an amino acid sequence having ≥45% homology with the amino acid sequence as shown in SEQ ID NO.1; compared with elastin from animal sources, the recombinant elastin of the present invention has the characteristics of better water solubility and lower immunogenicity, exhibits good biocompatibility and biological activity, can significantly promote the proliferation, adhesion and migration of human skin keratinocytes and fibroblasts, has a repair function for scalded skin, and can be widely used in skin repair dressings, fillers, implants, artificial blood vessels, artificial skin, drug delivery carriers, artificial bones, artificial cartilages, artificial corneas, biomaterials, medical devices, cosmetics and other fields;

[0036] Furthermore, the difficulty of heterologous expression of the recombinant elastin of the present invention is low, thereby increasing the yield of in vitro expression. The recombinant elastin is prepared by expression of genetically engineered bacteria, and the process is simple and convenient, and it is easy to realize industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0038] Figure 1 The SDS-PAGE electrophoresis results of the broken liquid before and after induction of the engineering bacteria BL21 / pET28a-rhELN in Example 2 of the present invention; wherein, M: Marker; Lane 1: broken liquid before induction; Lane 2: broken liquid after induction;

[0039] Figure 2It is the expression form and purification result of the engineered bacteria BL21 / pET28a-rhELN protein in Example 2 of the present invention; wherein, M: Marker; lane 1: post-induction broken liquid; lane 2: precipitate after centrifugation of the post-induction broken liquid; lane 3: supernatant after centrifugation of the post-induction broken liquid; lane 4: flow-through after the supernatant after centrifugation of the post-induction broken liquid was applied to a Ni column; lane 4: eluate after the supernatant after centrifugation of the post-induction broken liquid was applied to a Ni column;

[0040] Figure 3 is the secondary structure predicted by the protein in Example 3 of the present invention;

[0041] Figure 4 is a CD scan of the recombinant elastin in Example 3 of the present invention;

[0042] Figure 5 is the cell viability result in the cytotoxicity experiment in Experimental Example 1 of the present invention;

[0043] Figure 6 is the cell viability result in the cell proliferation experiment in Experimental Example 1 of the present invention;

[0044] Figure 7 is the cell viability result in the cell adhesion experiment in Experimental Example 1 of the present invention;

[0045] FIG8 (1) is a partial test result of the cell migration experiment in Experimental Example 1 of the present invention;

[0046] FIG8 (2) is the remaining test results of the cell migration experiment in Experimental Example 1 of the present invention;

[0047] Fig. 9 It is the healing result of sample cell migration injury in the cell migration experiment in Experimental Example 1 of the present invention;

[0048] Fig.10 is the cell viability result in the cytotoxicity experiment in Experimental Example 2 of the present invention;

[0049] Fig.11 is the cell viability result in the cell proliferation experiment in Experimental Example 2 of the present invention;

[0050] Fig.12 is the cell viability result in the cell adhesion experiment in Experimental Example 2 of the present invention;

[0051] FIG. 13 (1) is a partial test result of the cell migration experiment in Experimental Example 2 of the present invention;

[0052] FIG13(2) is the remaining test results of the cell migration experiment in Experimental Example 2 of the present invention;

[0053] Fig.14It is the healing result of sample cell migration injury in the cell migration experiment in Experimental Example 2 of the present invention;

[0054] Fig.15 This is a picture of the skin photographs of mice in each group on day 0 of Experimental Example 3 of the present invention;

[0055] Fig.16 This is a picture of the skin photographs of mice in each group on the 5th day of Experimental Example 3 of the present invention;

[0056] Fig.17 This is a picture of the skin photographs of mice in each group on the 10th day of Experimental Example 3 of the present invention;

[0057] Fig.18 This is a picture of the skin photographs of mice in each group on the 15th day of Experimental Example 3 of the present invention;

[0058] Fig.19 This is a quantitative result diagram of the skin wound recovery area of ​​each group of mice in Experimental Example 3 of the present invention. DETAILED DESCRIPTION

[0059] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the guidance of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0060] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be purchased commercially.

[0061] Example 1 Construction of the engineered bacteria BL21 / pET28a-rhELN expressing recombinant elastin

[0062] This embodiment provides a method for constructing an engineered bacterium BL21 / pET28a-rhELN, comprising the following steps:

[0063] (1) Design of target protein sequence: The present invention refers to the human elastin amino acid sequence Genebank accession number: NM_000501.4, and uses bioinformatics technology to analyze the amino acid sequence of GenBank: P15502.4, analyze the domain and its composition, secondary structure and hydrophilicity, etc., select 158 ​​amino acids to form a basic sequence (as shown in SEQ ID NO.1), and connect two basic sequences in series to form a new peptide segment (as shown in SEQ ID NO.2).

[0064] (2) Obtaining the target gene: The recombinant elastin gene was optimized according to the codon preference of Escherichia coli. The optimized target gene is shown in SEQ ID NO.3. Then, an NcoⅠ restriction site (5'-CCATGG-3') was added to the N-terminus of the optimized target gene, and a HindⅢ restriction site (5'-AAGCTT-3') and 6×His (5'-CATCACCACCATCATCAC-3') and a stop codon TAA were added to the C-terminus. The optimized gene sequence (shown in SEQ ID NO.4) was synthesized by Suzhou GeneWeizhi Co., Ltd.

[0065] (3) Construction of recombinant vector: Suzhou GeneWeizhi Co., Ltd. cloned the target gene optimized in step (2) into pET28a(+) to obtain the recombinant vector pET28a-rhELN.

[0066] (4) Transformation of recombinant vector: Take the recombinant vector pET28a-rhELN obtained in step (3) and mix it with the thawed Escherichia coli BL21 (DE3) competent cells, and place it on ice for 20 minutes. Place it in a 42°C water bath for heat shock for 90 seconds, and place it on ice again for 5 minutes. Add LB medium without resistance and culture it in a shaker at 37°C and 200rpm until the OD value is between 0.3-0.5. Centrifuge at 5000rpm for 1min, discard the supernatant, resuspend the precipitate, and evenly spread it on an agar plate containing 100μg / ml ampicillin (Ampicillin, Amp). Invert and culture at 37°C overnight. The next day, pick the transformed colony for inoculation and culture. Extract the plasmid from the overnight culture solution of the transformed colony, and if it is correct by nucleotide sequencing, the recombinant elastin expression engineered bacteria BL21 / pET28a-rhELN is obtained.

[0067] Example 2 Preparation of recombinant elastin

[0068] This embodiment provides a method for preparing recombinant elastin, comprising the following steps:

[0069] (1) Seed culture: The BL21 engineered bacteria BL21 / pET28a-rhELN (prepared in Example 1) carrying the pET28a-rhELN plasmid was streaked onto an LB agar plate containing 50 μg / ml of Amp and cultured at 37°C for 16 h. A single colony with good growth was picked and inoculated into an LB culture solution containing 50 μg / ml of Amp and cultured at 37°C overnight with shaking.

[0070] (2) Shake flask expression (fermentation liquid volume is 1L): The seed culture was inoculated into LB medium containing Amp resistance at a ratio of 5% (v / v) for rejuvenation, cultured at 37°C until the OD was about 0.6, IPTG was added with a final concentration of 0.2mM, and the temperature was lowered to 30°C for shaking culture induction for 5h. After harvesting the bacteria, they were resuspended in buffer (PBS with pH 8.0), ultrasonically disrupted (300W, ultrasonic for 5s, interval of 5s, ultrasonic for 12min), and centrifuged (12000rpm, 30min). A small amount of the disrupted bacteria (post-induction disrupted liquid), supernatant and precipitate were retained for 12% SDS-PAGE electrophoresis. At the same time, a control group was set up, and the culture liquid before IPTG induction was subjected to the same ultrasonic disruption, and the disrupted bacteria (pre-induction disrupted liquid) were retained for 12% SDS-PAGE electrophoresis. The expression level and expression form of the protein were analyzed. Results ( Figure 1 , Figure 2 ) showed that the detected protein size was approximately 29 kDa.

[0071] (3) Protein purification: The target protein was purified using the Bio-Lab purification system of Jiangsu Hanbang Technology Co., Ltd. A pre-packed Ni Bestarose FF (Fast Flow) nickel ion chelate affinity chromatography column from Bergeron was used. The Ni was washed with 5 column volumes of purified water. 2+ Chelate affinity chromatography column, and then balance it with equilibration buffer (50mM PB buffer, containing 0.5M Nacl, pH = 8.0) for 3 column volumes. Detect the conductivity value and 280nm wavelength absorption value online. After both are stable, start to load the protein sample (supernatant after crushing and centrifugation), and set the flow rate of the sample through the pump and chromatography column to 1min. Use 3 column volumes of equilibration buffer to pass through the chromatography column to wash away the impurities that are not bound to the chromatography column until the conductivity and ultraviolet wavelength 280nm are stable. Use 3 column volumes of elution buffer (50mM PB buffer, containing 0.5M Nacl, 250mM imidazole, pH = 8.0) to elute the target protein. The purified protein was analyzed by 12% SDS-PAGE electrophoresis ( Figure 2 ), with a purity higher than 90%.

[0072] Example 3 Determination of the secondary structure of recombinant elastin

[0073] Circular dichroism scanning analysis of proteins and polypeptides is very meaningful for studying their secondary structures and higher-order structures. Circular dichroism is a special absorption spectrum. It measures the circular dichroism of biological macromolecules such as proteins to obtain the secondary structure of biological macromolecules. It is simple and fast and is widely used in protein folding, protein conformation research, enzyme kinetics and other fields. The recombinant protein sample prepared in Example 2 was diluted to 0.02μg / μL with a blank control solution (PBS, pH=7.4), and the parameters were set to a starting wavelength of 190nm, an end wavelength of 260nm, a scanning speed of 50nm / min, a response of 4sec, a bandwidth of 1nm, 3 detection times, and a cuvette width of 1cm. The blank control solution was loaded with a loading volume of 300μL and deducted after measurement. Then the sample was tested with a loading volume of 300μL.

[0074] Test results such as Figure 4 The figure shows the CD scan of recombinant elastin. The horizontal axis represents the scanning wavelength and the vertical axis represents the ellipticity. The CDNN software is used to fit and calculate the secondary structure of the sample, including Helix, Antiparallel, Parallel, Beta-Turn, and Rndm.Coil. Since the prediction results may have errors, the analysis results are shown in Tables 1 and Figure 3 As shown in the figure, it shows that the predicted results are basically consistent with the test results.

[0075] Table 1. Calculation of secondary structure ratio in samples

[0076] sample spiral Antiparallel β-sheet Parallel β-sheet β-turn Irregular curl Diluted recombinant protein samples 5.80% 9.00% 1.90% 37.80% 52.30%

[0077] Experimental Example 1: Surface cytological experiment of recombinant elastin

[0078] 1. Cytotoxicity assay

[0079] Human immortalized keratinocytes (HCat) grown completely on the wall were digested with trypsin and cultured in complete culture medium (1% FBS, 2% Penicillin-Streptomycin, DMEM medium) to a cell density of 1×10 5 100 μl of cell suspension was transferred to each 96-well culture plate and placed in a 37°C, 5% CO 2Incubate the cells overnight in an incubator until the cell plating rate reaches 40% to 60%. Aspirate the complete culture medium, adjust the initial concentration of the recombinant elastin (prepared in Example 2) to 2.2 mg, and then use fresh complete culture medium to prepare sample working solutions of different concentrations according to the test concentration setting table (Table 2). Add 200 μl of complete culture medium containing 10% PBS to each well of the negative control group; add 200 μl of complete culture medium containing 10% DMSO to each well of the positive control group (PC); add 200 μl of sample working solution containing samples of corresponding concentrations to each well of the sample group; the zero adjustment group has no cell inoculation and only adds 200 μl of cell culture medium. After the administration is completed, place the 96-well plate in an incubator (37°C, 5% CO 2 ) and cultured the cells for 24 h. The supernatant was discarded and 200 μl of culture medium containing 0.5 mg MTT was added. The cells were incubated at 37°C in the dark for 2 h. After the incubation, the supernatant was discarded and 100 DMSO was added to each well. The OD value was read at 490 nm.

[0080] Table 2 Test concentration setting table

[0081]

[0082] Calculation of relative cell viability:

[0083]

[0084] The experimental results are shown in Table 3 and Figure 5 As shown, compared with the control group, the cell survival rate at different volume concentrations was greater than 95%, indicating that the recombinant elastin designed by the present invention has no toxicity to cells.

[0085] Table 3 Cytotoxic MTT test results

[0086]

[0087]

[0088] 2. Cell Proliferation Assay

[0089] Human skin immortalized keratinocytes (HCat) were cultured in the complete culture medium as described above, collected during the logarithmic growth phase, and cultured at a cell density of 8×10 4 Each well was inoculated into a 12-well culture plate and incubated in an incubator (37°C, 5% CO 2) for 24 hours, and then add samples according to Table 4 (elastin is the elastin prepared in Example 2, denoted as E002, prepared with complete culture medium without FBS). 72 hours after sample loading, the supernatant was discarded, 500 μl of culture medium containing 0.5 mg of MTT was added, and the cells were incubated at 37°C in the dark for 2 hours. After the incubation, the supernatant was discarded, 300 μl of DMSO was added to each well, and the OD value was read at 490 nm.

[0090] Table 4 Cell proliferation design table

[0091]

[0092] Calculation of relative cell viability:

[0093]

[0094] The experimental results are shown in Table 5 and Figure 6 As shown, after the cells were cultured for 72 hours, the cell viability in the positive control group was significantly higher than that in the negative control group (p<0.01); compared with the negative control group, the cell viability was significantly increased after treatment with 0.63%, 2.5% and 5% (V / V) samples (p<0.01), showing the effect of promoting the proliferation of immortalized keratinocytes of human skin.

[0095] Table 5 Summary of cell viability results

[0096]

[0097] ** indicates comparison with the BC group, p < 0.01.

[0098] 3. Cell Adhesion Assay

[0099] 1) Coating culture plate: 10 μg of type I collagen (Collagen I) was coated on a 96-well plate and kept in a refrigerator at 4°C overnight.

[0100] 2) BSA washing: aspirate the coating solution, add 200 μL of heat-denatured 1% BSA and incubate the plate at 37°C for 1 hour.

[0101] 3) Culture medium immersion: Wash the plate twice with serum-free culture medium.

[0102] 4) Preparation of cell suspension: digest cells (human immortalized keratinocytes (HCat) from human skin, culture medium is complete culture medium) with trypsin to prepare cell suspension, wash cells with serum-free medium and resuspend them.

[0103] 5) Seed plate: Collect cells in logarithmic growth phase and set the cell density at 5×10 4 Each well was plated in a pre-treated 96-well plate.

[0104] 6) Sample loading: Samples were added according to Table 6. The elastin was the elastin prepared in Example 2 and was recorded as E002. The complete culture medium without FBS was used for preparation. The culture medium in the culture conditions was the complete culture medium.

[0105] 7) Detection: 6 hours after loading, discard the supernatant, wash the non-adherent cells with PBS, add 100 μl of culture medium containing 0.5 mg MTT, incubate at 37°C in the dark for 2 hours, discard the supernatant after incubation, add 50 μl DMSO to each well, and read the OD value at 490 nm.

[0106] 8) Calculation of relative cell viability:

[0107]

[0108] Table 6 Cell adhesion design table

[0109]

[0110]

[0111] The results are shown in Table 7 and Figure 7 The results showed that compared with the BC group, the keratinocyte viability in the NC group was significantly increased (p < 0.05), indicating that the plate coating was effective; compared with the NC group, the serum in the PC group could significantly increase the keratinocyte viability (p < 0.01), indicating that the positive control test was effective; compared with the NC group, the samples at 0.63%, 2.5% and 5% (V / V) concentrations showed a significant improvement in the keratinocyte viability (p < 0.01). This shows that the sample elastin has the effect of promoting the adhesion of immortalized keratinocytes of human skin.

[0112] Table 7 Summary of cell viability results

[0113]

[0114] # indicates comparison with the BC group, p < 0.05; ** indicates comparison with the NC group, p < 0.01.

[0115] 4. Cell Migration Assay

[0116] 1) Collect cells in logarithmic growth phase (human immortalized keratinocytes (HCat), culture medium is complete culture medium), and set the cell density at 2×10 5 Each well was inoculated into a 24-well culture plate.

[0117] 2) Incubate in an incubator (37°C, 5% CO 2 ) for 24 h, a 200 μl pipette tip was used to scratch a “lesion” on a 24-well plate, and the cells were washed three times with PBS to remove the scratched cells.

[0118] 3) Load the samples according to Table 8. The elastin is the elastin prepared in Example 2 and is recorded as E002. The complete culture medium without FBS is used. The culture medium in the culture conditions is the complete culture medium. Place in an incubator (37°C, 5% CO 2 ) were cultured for 24 h, with 3 parallels in each group.

[0119] 4) Use an inverted microscope to take pictures of each group of migrated cells, and use Image Pro Plus software to calculate the average scratch area.

[0120] Healing rate % = (initial scratch area - current scratch area) / initial scratch area × 100%.

[0121] Table 8. Cell migration design table

[0122]

[0123] The test results are shown in Figure 8(1) and Figure 8(2) and the results analysis is shown in Table 9 and Fig. 9 In the cell migration test, compared with the BC group, the cell healing rate of human skin immortalized keratinocytes (HaCaT) treated with elastin at concentrations of 0.63%, 2.5% and 5% (V / V) was significantly improved (p<0.01), indicating that the samples have cell repair effects.

[0124] Table 9 Summary of cell healing rate results

[0125]

[0126] ** indicates comparison with the BC group, p < 0.01.

[0127] Experimental Example 2: Dermal Cellular Experiment of Recombinant Elastin

[0128] 1. Cytotoxicity assay

[0129] Human skin fibroblasts (human dermal fibroblasts) that fully adhered to the wall were digested with trypsin and cultured in complete culture medium (1% FBS, 2% Penicillin-Streptomycin, DMEM medium) to a cell density of 8×10 3 The cells were inoculated into a 96-well culture plate and placed at 37°C and 5% CO. 2Incubate overnight in an incubator to make the cell plating rate reach 40% to 60%, aspirate the complete culture medium, the initial concentration of recombinant elastin (prepared in Example 2) is 2.2 mg, prepare sample working solutions of different concentrations according to the test concentration setting table (Table 2 in Experimental Example 1), add 200 μl of culture solution containing 10% PBS to each well of the control group; add 200 μl of culture solution containing 10% DMSO to each well of the positive control group; add 200 μl of culture solution containing samples of corresponding concentrations to each well of the sample group; the zeroing group has no cell inoculation, and only 200 μl of cell culture solution is added. After the administration is completed, place the 96-well plate in an incubator (37°C, 5% CO 2 ) and cultured the cells for 24 hours, discarded the supernatant, added 200 μl of culture medium containing 0.5 mg MTT, and incubated at 37°C in the dark for 2 hours. After the incubation, discarded the supernatant, added 100 μl of DMSO to each well, and read the OD value at 490 nm. Calculation of relative cell viability:

[0130]

[0131] The experimental results are shown in Table 10 and Fig.10 As shown, according to the MTT results, the sample showed no cytotoxicity within the concentration range of 10.00% (V / V), indicating that the recombinant elastin designed by the present invention has no toxicity to cells.

[0132] Table 10 Cytotoxic MTT test results

[0133]

[0134]

[0135] 2. Cell Proliferation Assay

[0136] Cells in logarithmic growth phase (human skin fibroblasts, cultured in complete culture medium) were collected and cultured at a cell density of 8×10 4 Each well was inoculated into a 12-well culture plate and incubated in an incubator (37°C, 5% CO 2 ) and cultured for 24 hours, and then added samples according to Table 11. The elastin was prepared in Example 2 and recorded as E002. The complete culture medium without FBS was used, and the culture medium in the culture conditions was the complete culture medium. After 72 hours after the sample was added, the supernatant was discarded, and 500 μl of culture medium containing 0.5 mg MTT was added, and the cells were incubated at 37°C in the dark for 2 hours. After the incubation, the supernatant was discarded, 300 μl DMSO was added to each well, and the OD value was read at 490 nm. Calculation of relative cell viability:

[0137]

[0138] Table 11 Cell proliferation design table

[0139]

[0140] The experimental results are shown in Table 12 and Fig.11 As shown, after the cells were cultured for 72 hours, the cell viability in the positive control group was significantly higher than that in the negative control group (p<0.01); compared with the negative control group, the cell viability was significantly increased after treatment with 0.63%, 2.5% and 5% (V / V) samples (p<0.01), showing the effect of promoting the proliferation of human skin fibroblasts.

[0141] Table 12 Summary of cell viability results

[0142]

[0143] ** indicates comparison with the BC group, p < 0.01.

[0144] 3. Cell Adhesion Assay

[0145] 1) Coated culture plate: 10 μg Collagen I was coated on a 96-well plate and kept in a 4°C refrigerator overnight.

[0146] 2) BSA washing: aspirate the coating solution, add 200 μl of heat-denatured 1% BSA and incubate the plate at 37°C for 1 h.

[0147] 3) Culture medium immersion: Wash the plate twice with serum-free culture medium.

[0148] 4) Preparation of cell suspension: Digest cells (human skin fibroblasts, culture medium is complete culture medium) with trypsin to prepare cell suspension, wash cells with serum-free culture medium and resuspend them.

[0149] 5) Seed plate: Collect cells in logarithmic growth phase and set the cell density at 2×10 4 Each well was plated in a pre-treated 96-well plate.

[0150] 6) Loading: Samples were added according to Table 13. The elastin was the elastin prepared in Example 2 and was recorded as E002. The complete culture medium without FBS was used for preparation. The culture medium in the culture conditions was the complete culture medium.

[0151] 7) Detection: 6 hours after loading, discard the supernatant, wash the non-adherent cells with PBS, add 100 μl of culture medium containing 0.5 mg MTT, incubate at 37°C in the dark for 2 hours, discard the supernatant after incubation, add 50 μl DMSO to each well, and read the OD value at 490 nm.

[0152] 8) Calculation of relative cell viability:

[0153]

[0154] Table 13 Cell adhesion design table

[0155]

[0156] The results are shown in Table 14 and Fig.12 The results showed that compared with the BC group, the keratinocyte viability in the NC group was significantly increased (p < 0.05), indicating that the plate coating was effective; compared with the NC group, the serum in the PC group could significantly increase the keratinocyte viability (p < 0.01), indicating that the positive control test was effective; compared with the NC group, the samples at 0.63%, 2.5% and 5% (V / V) concentrations showed a significant improvement in the viability of fibroblasts (p < 0.05). This shows that the sample elastin has the effect of promoting the adhesion of human skin fibroblasts.

[0157] Table 14 Summary of cell viability results

[0158]

[0159] ## indicates comparison with BC group, p<0.01; * indicates comparison with NC group, p<0.05; ** indicates comparison with NC group, p<0.01.

[0160] 4. Cell Migration Assay

[0161] 1) Collect cells in logarithmic growth phase (human skin fibroblasts, culture medium is complete culture medium), and culture at a cell density of 1×10 5 Each well was inoculated into a 24-well culture plate.

[0162] 2) Incubate in an incubator (37°C, 5% CO 2 ) for 24 h, a 200 μm pipette tip was used to scratch a “lesion” on a 24-well plate, and the cells were washed three times with PBS to remove the scratched cells.

[0163] 3) Load the samples according to Table 15. The elastin is the elastin prepared in Example 2 and is recorded as E002. The complete culture medium without FBS is used. The culture medium in the culture conditions is the complete culture medium. Place in an incubator (37°C, 5% CO 2 ) were cultured for 24 h, with 3 parallels in each group.

[0164] 4) Use an inverted microscope to take pictures of each group of migrated cells, and use Image Pro Plus software to calculate the average scratch area.

[0165] Healing rate % = (initial scratch area - current scratch area) / initial scratch area × 100%

[0166] Table 15. Cell migration design table

[0167]

[0168] The test results are shown in Figures 13(1) and 13(2) and the results analysis is shown in Tables 16 and Fig.14 In the cell migration test, compared with the BC group, the cell healing rate of human skin fibroblasts treated with samples of elastin at concentrations of 0.63%, 2.5% and 5% (V / V) was significantly improved (p<0.01), indicating that the samples have cell repair effects.

[0169] Table 16. Cell healing rate results

[0170]

[0171] ** indicates comparison with the BC group, p < 0.01.

[0172] Experimental Example 3: Animal injury repair experiment of recombinant elastin

[0173] 30 adult SD male rats were selected, weighing 200g±20g, and the hair was shaved with a razor to completely expose the epidermis, and a shallow II SD rat burn model was made (reference to YY / T1477.2-2016 standard), divided into five groups, 6 in each group, the first group was a negative control group, the second group was Chongqing Kangzhimei elastin sample (trade name hydrolyzed elastic collagen, article number KM-700A), the third group and the fourth group were experimental groups, and the fifth group was an epidermal growth factor (trade name medical recombinant human epidermal factor type, article number medical liquid wound dressing) positive control group, the recombinant elastin prepared in Example 2 was adjusted to a low concentration of 2.5mg / ml for the third group, and a high concentration of 5mg / ml was adjusted for the fourth group. The second, third, and fourth groups were sprayed 3-5 times a day with a spray bottle until the surface was moist, and the fifth group was smeared with a cotton swab, and the medication was given once a day for a total of fifteen days, and the results were recorded every five days. SPSS 20.0 statistical software was used to process the data, and GraphPad prism 5.0 software was used to draw the graph. All quantitative data in the experimental data were expressed as mean ± standard deviation, and two independent sample t tests were used for comparison when analyzing the quantitative data of the two groups. All experiments were repeated at least 3 times, and the differences were considered statistically significant when P < 0.05.

[0174] Representative rat skin photos are shown below. Figure 15-18 As shown, the wounds of the experimental group rats began to scab and fall off on the 10th day, and the wounds of the high-concentration treatment group completely fell off on the 15th day, while the wounds of the negative control group and the positive control group did not fall off completely. Fig.19As shown, there was no significant difference in the treatment results of the five groups in the first five days. From the tenth day to the fifteenth day, the wound healing of rats in the second to fifth treatment groups showed significant differences (*p<0.05, **p<0.01, ***p<0.001). Among them, on the tenth day, the wound healing of the high-concentration experimental group using the recombinant elastin prepared in Example 2 recovered faster than the wound healing area of ​​the fifth group (**p<0.01); on the fifteenth day, the wound healing area of ​​the high-concentration recombinant elastin prepared in Example 2 recovered faster than that of the low-concentration recombinant elastin (***p<0.001), and the wound healing area of ​​the high-concentration recombinant elastin prepared in Example 2 recovered faster than that of the fifth group (*p<0.05). These results show that the recombinant elastin prepared in the present invention has a repair function for the scalded skin of rats and can accelerate the repair cycle of the skin.

[0175] The above experimental results show that the recombinant elastin prepared by the present invention exhibits good biocompatibility and biological activity, can significantly promote the proliferation, adhesion and migration of human skin keratinocytes and fibroblasts, and has a repair function for scalded skin, so the recombinant elastin prepared by the present invention with biological activity can be widely used in the fields of skin repair dressings, fillers, implants, artificial blood vessels, artificial skin, drug delivery carriers, artificial bones, artificial cartilage, artificial corneas, biomaterials, medical devices, cosmetics, etc. In addition, the present invention prepares recombinant elastin by expression of genetically engineered bacteria, and the process is simple and convenient, and it is easy to realize industrial production.

[0176] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the present invention.

Claims

1. A recombinant elastin protein, characterized in that: The amino acid sequence of the recombinant elastin is the amino acid sequence shown in SEQ ID NO.

2.

2. A biomaterial, characterized in that: Includes any of the following: (1) A nucleic acid molecule encoding the recombinant elastin protein according to claim 1; (2) A recombinant vector containing the nucleic acid molecule described in (1); (3) A host cell containing the nucleic acid molecule described in (1) or the recombinant vector described in (2).

3. The biomaterial according to claim 2, characterized in that The nucleic acid molecule is codon optimized.

4. The biomaterial according to claim 3, characterized in that The nucleic acid molecule comprises a nucleotide sequence of an NcoⅠ restriction site, a HindⅢ restriction site, a termination codon and / or a 6×His tag.

5. The biomaterial according to claim 4, characterized in that The nucleotide sequence of the NcoⅠ restriction site is 5'-CCATGG-3'; And / or, the nucleotide sequence of the HindⅢ restriction site is 5'-AAGCTT-3'; and / or, the nucleotide sequence of the stop codon is 5'-TAA-3'; And / or, the nucleotide sequence of the 6×His tag is 5′-CATCACCATCACCATCAT-3′.

6. The biomaterial according to any one of claims 2 to 5, characterized in that: The starting vector of the recombinant vector includes pCold, pET or pPIC9K.

7. The biomaterial according to any one of claims 2 to 5, characterized in that: The host cell includes Escherichia coli, Pichia pastoris or Saccharomyces cerevisiae.

8. A method for preparing recombinant elastin as claimed in claim 1, characterized in that: The nucleic acid molecule encoding the recombinant elastin of claim 1 is connected to a vector to obtain a recombinant vector, which is then transformed into a host cell, fermented, and the bacterial cell precipitate is collected, crushed to obtain a supernatant, and purified.

9. Use of the recombinant elastin as claimed in claim 1 in preparing a product for promoting skin repair.

10. The use according to claim 9, characterized in that The product may be a skin repair dressing, a filler, an implant or an artificial skin.

11. A skin repair product, characterized in that: The invention comprises the recombinant elastin as claimed in claim 1 as an active ingredient and also comprises an acceptable carrier or excipient.

Citation Information

Cited By

  • Sterile plant flower water stock solution as well as preparation method and application thereof

    CN120324313A

  • Responsive release microcapsule as well as preparation method and application thereof

    CN120324589A

  • Responsive release microcapsules, methods of making and using the same

    CN120324589B

  • Pyrrolidone carboxylic acid-lysozyme compound as well as preparation method and application thereof

    CN120485158A

  • A pyrrolidone carboxylic acid-lysozyme complex, its preparation method and use

    CN120485158B